omniture
logo
Search
ABBISKO THERAPEUTICS上海和誉生物
Media Room

Latest News

rss

77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting

SHANGHAI, May 28, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" herea...

2023-05-28 21:00 4399
77.4% ORR! Abbisko to present the updated clinical phase Ib data of Pimicotinib (ABSK021) at the 2023 ASCO Annual Meeting

Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting

SHANGHAI, April 17, 2023 /PRNewswire/ -- Abbisko (Stock Code: 2256.HK) announced the results of fiv...

2023-04-17 08:30 4351
Abbisko presents the research results of 5 programs at the 2023 AACR Annual Meeting

The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial

This is the first-ever global phase III trial for TGCT approved by NMPA and FDA. Pimicotinib（ABSK02...

2023-03-16 10:00 5310
The FDA has approved the CSF-1R inhibitor Pimicotinib (ABSK021) of Abbisko Therapeutics to enter the Pivotal Global Multi-center Phase III Clinical Trial

Abbisko Therapeutics Announces an Out-License Agreement with Allist for ABK3376

SHANG HAI, March 2, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" her...

2023-03-02 19:15 5047

Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）

SHANGHAI, Jan. 30, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" here...

2023-01-30 11:00 5325
Abbisko Therapeutics announces that US FDA has granted breakthrough therapy designation for its CSF-1R inhibitor Pimicotinib（ABSK021）

Abbisko Therapeutics Obtains Approval from The China NMPA to Conduct a Phase II Clinical Study of Pimicotinib (ABSK021） in cGVHD

SHANGHAI, Jan. 18, 2023 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" here...

2023-01-18 07:00 4298

Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061

SHANGHAI, July 4, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. (HKEX Stock Code: 2256.HK, re...

2022-07-04 13:34 2977
Abbisko Therapeutics Completed Dosing of First Patient for Its First-in-Class Highly Selective FGFR2/3 Inhibitor ABSK061

Abbisko Therapeutics Announces Worldwide Collaboration with Lilly to Discover and Develop Novel Molecules

SHANGHAI, Jan. 17, 2022 /PRNewswire/ -- Abbisko Therapeutics Co., Ltd. ("Abbisko Therapeutics" here...

2022-01-18 10:41 2742
12